Back to today’s briefing

Story perspectives

UNITY Biotechnology to Reveal Phase 2b Results on UBX1325

3/24/2025

45 9

Summary

Story summary

Mark your calendars for March 24, 2025, at 8:00 AM ET! UNITY Biotechnology invites you to a virtual investor event where Dr. Robert Bhisitkul will unveil exciting results from the Phase 2b ASPIRE study on UBX1325. This innovative treatment aims to combat diabetic macular edema by targeting senescent cells, promising brighter visual outcomes for patients.

1 of 1

Story summary

Mark your calendars for March 24, 2025, at 8:00 AM ET! UNITY Biotechnology invites you to a virtual investor event where Dr. Robert Bhisitkul will unveil exciting results from the Phase 2b ASPIRE study on UBX1325. This innovative treatment aims to combat diabetic macular edema by targeting senescent cells, promising brighter visual outcomes for patients.